Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | developmentally regulated phosphoprotein, putative | 0.2229 | 1 | 0.5 |
Echinococcus granulosus | Pyruvate dehydrogenase lipoamide kinase | 0.2229 | 1 | 0.5 |
Trypanosoma brucei | developmentally regulated phosphoprotein | 0.2229 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.2229 | 1 | 0.5 |
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.2229 | 1 | 0.5 |
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.2229 | 1 | 0.5 |
Leishmania major | developmentally regulated phosphoprotein-like protein | 0.2229 | 1 | 0.5 |
Schistosoma mansoni | pyruvate dehydrogenase | 0.2229 | 1 | 1 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.0903 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | Anticonvulsant activity in Mus musculus albino (mouse) assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 4 hr | ChEMBL. | No reference | |
Activity (functional) | Anticonvulsant activity in Mus musculus albino (mouse) assessed as protection against subcutaneous pentylenetetrazol-induced seizures at 300 mg/kg, ip after 0.5 hr | ChEMBL. | No reference | |
Activity (functional) | Anticonvulsant activity in Mus musculus albino (mouse) assessed as protection against subcutaneous pentylenetetrazol-induced seizures at 300 mg/kg, ip after 4 hr | ChEMBL. | No reference | |
MED (functional) | = 300 mg kg-1 | Anticonvulsant activity in ip dosed Mus musculus albino (mouse) assessed as protection against maximal electroshock-induced seizures after 0.5 hr | ChEMBL. | No reference |
MTC (ADMET) | = 300 mg kg-1 | Neurotoxicity in ip dosed Mus musculus albino (mouse) after 4 hr rotorod test | ChEMBL. | No reference |
MTC (ADMET) | = 300 mg kg-1 | Neurotoxicity in ip dosed Mus musculus albino (mouse) after 0.5 hr rotorod test | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.